Home

DAVID NATAN

CIK 1253108 · CEO · last filed 2026-05-21

DAVID NATAN is a CEO who has filed 27 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for QUCY, was dated May 21, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $917.6K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$917.6K

Companies

10

Total Filings

27

Lifetime Open-Market Net

-$1.53M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
QUCY Director 137,141 $1.09 $149.5K $0 1 2026-05-21
FIEE Director 248,792 $2.83 $704.1K $0 1 2026-05-07
SBFMW Director 100,000 $0.06 $5.5K $0 1 2026-04-14
SOWG Director 18,458 $3.17 $58.5K $0 1 2026-04-01
INDP Director — $1.73 — $0 1 2026-01-22
Bio Green Med Solution, Inc. (CYCCP) Delisted Director 100,000 $5.05 $505.0K $0 2 2025-02-28
FiEE, Inc. (MINM) Delisted Director 146,792 $3.61 $529.9K $0 2 2024-10-01
OPGEN INC (OPGN) Delisted Director 10,000 $24.75 $247.5K $0 1 2024-04-12
TITAN PHARMACEUTICALS INC (TTNP) Delisted Director 3,312 $4.61 $15.3K $0 3 2023-10-26
PharmaNet Development Group Inc (PDGI) Delisted Former EVP 7,766 — — -$1.53M 6 2007-12-12

Recent Filings

27 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-21 QUCY Grant (A) +137,141 $0 EDGAR
2026-05-07 FIEE Grant (A) +100,000 $0 EDGAR
2026-04-14 SBFMW Grant (A) +100,000 $0 EDGAR
2026-04-01 SOWG Grant (A) +276,876 $128.8K EDGAR
2026-01-22 INDP Grant (A) — $0 EDGAR
2025-02-28 Bio Green Med Solution, Inc. (CYCCP) Delisted Grant (A) — $0 EDGAR
2025-01-07 Bio Green Med Solution, Inc. (CYCCP) Delisted Grant (A) +100,000 $0 EDGAR
2024-10-01 FiEE, Inc. (MINM) Delisted Grant (A) +121,792 $0 EDGAR
2024-04-12 OPGEN INC (OPGN) Delisted Grant (A) +100,000 $0 EDGAR
2024-01-24 FiEE, Inc. (MINM) Delisted Grant (A) +25,000 $0 EDGAR
Showing 1–10 of 27
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.